Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year
Advertisement

Related Content

Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Worries About Future Healthcare Costs Could Restrict Healthcare Spending Today By Asia Consumers
Novo Nordisk CEO Lars Sørensen: An Interview With "The Pink Sheet"
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D
Lilly Launches Byetta In China To Target World's Second Largest Diabetes Market
Lilly Launches Byetta In China To Target World's Second Largest Diabetes Market
Advertisement
UsernamePublicRestriction

Register

SC077465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel